Improving Driving in Young People With Autism Spectrum Disorders

• Status: Completed
• Trial end date: 2019-12-16
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD).

The study consists of an Assessment Visit at Massachusetts General Hospital (MGH), as well as two Driving Simulation visits that will take place at Massachusetts Institute of Technology (MIT). Subjects will be given buspirone and asked to take the medication for the two days preceding the Driving Simulation Visit.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Massachusetts Institute of Technology
• Treatments: Buspirone

Criteria

Inclusion Criteria:

• Males and females, ages 18-24, with a diagnosis of DSM-V Autism Spectrum Disorder

• Has a valid Driver's License

Exclusion Criteria:

• Major sensorimotor handicaps (e.g. deafness, blindness)

• Individuals who have never held a valid driver's license

• Intellectual Deficiency (Verbal Comprehension Index < 80)

• Inadequate command of the English language

• Subjects with any clinically meaningful medical or psychiatric condition as determined by the investigator

• Individuals who are currently taking a monoamine oxidase inhibitor (MAOI) for any reason

• Pregnant